Results from the Phase 3 trial (NCT04951622) evaluating nipocalimab for generalized myasthenia gravis were posted on 2023-11-17. The study demonstrated that nipocalimab significantly reduced the Myasthenia Gravis - Activities of Daily Living (MG-ADL) total score compared to placebo, with a difference of least squares means of -1.45 (p=0.002).

Background

This study investigated nipocalimab for the treatment of generalized myasthenia gravis (gMG). Generalized myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by weakness in the voluntary muscles.

Trial design

The Phase 3 study (NCT04951622) enrolled 199 participants with generalized myasthenia gravis. It aimed to evaluate the efficacy and safety of nipocalimab compared to placebo. The primary outcome measured was the average change from baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) total score over weeks 22, 23, and 24. Participants received either nipocalimab (intravenous or subcutaneous) or placebo.

Key results

  • In the double-blind phase, the average change from baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) total score over weeks 22, 23, and 24 for the placebo group was a least squares mean of -3.25 (Standard Error 0.335).
  • For the nipocalimab group, the average change from baseline in MG-ADL total score over weeks 22, 23, and 24 was a least squares mean of -4.70 (Standard Error 0.329).
  • The difference of least squares means between nipocalimab and placebo was -1.45, with a 95.0% confidence interval ranging from -2.38 to -0.52. This difference was statistically significant (p=0.002).

What this means

The statistically significant reduction in the MG-ADL total score observed with nipocalimab compared to placebo indicates a positive therapeutic effect for adults with generalized myasthenia gravis. The difference in least squares means of -1.45 (p=0.002) suggests that nipocalimab may offer a meaningful improvement in daily living activities for patients. These results support its potential as a treatment option for gMG.

Source

This information was sourced from ClinicalTrials.gov, detailing trial results posted on 2023-11-17 for study NCT04951622. The full details are available on clinicaltrials.gov.